Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biohaven (BHVN) to $18 from $21 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Trump Trade: Trump to suspend tariff-rate quotas on beef imports
- Biohaven: Hold Rating Reiterated as Clinical and Competitive Uncertainties Persist; Price Target Maintained at $10
- Trump Trade: U.S. plans AI security order without required model tests
- Trump approves plan to fire FDA head Marty Makary, CBS reports
- Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures